Equibles does not estimate personal net worth.
Get an email with a short summary when Biomarin Pharmaceutical Inc publishes a filing, an earnings call transcript or a press release.
Get BMRN alertsBrian Mueller is recorded as CFO at Biomarin Pharmaceutical Inc (BMRN). The newest filing on record that lists Brian Mueller as CFO at Biomarin Pharmaceutical Inc (BMRN) is dated April 21, 2026. The proxy statement of Biomarin Pharmaceutical Inc reports total compensation of $6,831,812 for Brian Mueller in fiscal 2025, including a base salary of $721,154. Disclosed compensation is on record for 8 fiscal years. Brian Mueller has spoken on 27 earnings calls and 2 other investor events across 1 company, most recently for Biomarin Pharmaceutical Inc on November 11, 2026. Biomarin Pharmaceutical Inc is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Biomarin Pharmaceutical Inc includes Alexander Hardy (CEO and Board Member), Richard A. Meier (Chairman), Daniel Spiegelman (CFO) and 7 others.
“We're just a week out of our Q3 report, and lots of strong progress and results this year. We are executing on one of the core elements of our strategy, which is using our financial strength to fund future innovation.”
“Please refer to today's press release for detailed third-quarter 2026 results, including reconciliations of gap-to-non-gap financial measures, as well as our upcoming Form 10-Q. As Alexander and Kristen have already covered the key revenue details for Q3, I will cover the financial impact of our two recent business…”
“Yeah, so I do think there's some folks that may not be familiar with Biomarin, so I thought I'd give a little bit of maybe the past, present, and future, and then we can get into more details in the business.”
“Please refer to today's press release for detailed second quarter 2026 results including reconciliations of gap to non-gap financial measures which will also be available in our upcoming form 10q turning to slide 19 we were pleased that second quarter revenue reached nearly 1 billion dollars representing 20 top line…”
“Please refer to today's press release for detailed first quarter 2026 results, including reconciliations of gap to non-GAAP financial measures. All first quarter results will be available in our upcoming Form 10-Q, which we expect to file in the coming days.”
Start not stated–present
Last confirmed April 21, 2026
Biotechnology · Healthcare
CFO
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Biomarin Pharmaceutical Inc (BMRN) | Executive Vice President, CFO | $721,154 | $6,831,812 |
| 2024 | Biomarin Pharmaceutical Inc (BMRN) | Executive Vice President, CFO | $699,231 | $5,498,568 |
| 2023 | Biomarin Pharmaceutical Inc (BMRN) | Executive Vice President, CFO | $666,346 | $4,854,192 |
| 2022 | Biomarin Pharmaceutical Inc (BMRN) | Executive Vice President, CFO | $624,231 | $5,107,284 |
| 2021 | Biomarin Pharmaceutical Inc (BMRN) | Executive Vice President, Finance and CFO | $600,000 | $4,699,165 |
| 2020 | Biomarin Pharmaceutical Inc (BMRN) | Executive Vice President, Finance and CFO | $600,923 | $5,840,531 |
| 2019 | Biomarin Pharmaceutical Inc (BMRN) | Executive Vice President, Finance and CFO | $417,235 | $1,676,536 |
| 2018 | Biomarin Pharmaceutical Inc (BMRN) | Executive Vice President and Chief Financial Officer | $402,712 | $1,524,685 |
